Drug intelligence / Profile preview

BT-409

Development stage: Preclinical
Lead developer: Brenig Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

BT-409 is an orally administered, highly selective, brain-penetrant small-molecule inhibitor of the NLRP3 inflammasome, designed specifically for central nervous system (CNS) activity with minimal on- and off-target side effects. Its development aims to address neuroinflammation in diseases such as Parkinson's disease and other neurodegenerative disorders. The drug demonstrated a promising safety and pharmacokinetic profile in preclinical neuroinflammation models. Originally designed by Mwyngil Therapeutics through a drug discovery partnership with Torrey Pines and OrbiMed, BT-409 was acquired by Brenig Therapeutics, which intends to move the drug into Phase 1 safety studies for CNS diseases[1][4][10].

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on BT-409.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BT-409.

Explore the full profile